An always-ready FDA/EMA audit — the inspection walks in “prepared” because the evidence is live, not filed away.
Preparing an FDA or EMA inspection normally means months of sprint in which QA rebuilds dossiers, hunts for signatures and prays that nobody changed the template along the way. iLEAN keeps GMP evidence live and consolidated continuously — the inspection walks in and reads, it does not wait. The QA person signs every release of information — the system only assembles the dossier properly.
The pre-inspection sprint is a symptom — the evidence is not where it needs to be.
The pre-inspection sprint routine is always the same:
- The inspection is announced, or the notified body's Q-Submitter gives notice. The clock starts running.
- QA freezes the normal plan for the quarter and sets up a sprint that lasts between 6 and 12 weeks. Daily meetings, old dossiers rebuilt, missing signatures, templates that changed without telling production.
- You look back over 2-3 years of batches to anticipate what the inspector might ask. SOPs that were "in force" but were not applied on the floor get rewritten. A script of answers is prepared.
- The inspector walks in. The quality manager's memory is worth the entire dossier — get one date wrong on a cleaning question and out comes a 483.
- After the sprint, the plant takes 3 months to get back to its normal pace, because half of the QA team was in inspection mode instead of continuous improvement.
And the underlying problem is not that QA does not know how to do its job. The problem is that the evidence lives in islands: batch records as signed PDFs in a folder, the MES audit trail in another system, change control in SharePoint, calibrations in the maintenance manager's spreadsheet, training in the HR LMS. Every inspection forces you to rebuild the bridge between all those islands — and rebuilding it is what eats the 6-12 weeks.
iLEAN is not another document repository — it is the putty that keeps the evidence consolidated continuously.
The pre-inspection sprint disappears when the evidence is already consolidated the day the inspector calls. iLEAN acts as the putty between your MES, SCADA, LIMS, ERP, change control system, training LMS and the operator's notebook: it reads what each system knows, cross-references it with the SOP in force and the applicable regulation, and keeps the dossiers by product, batch, process and deviation alive. The inspection does not create new work — it creates reading.
Tracer captures the evidence wherever it is. Writer keeps the dossier alive by product and process. The agent cross-references it with the regulation and prepares the answers with their evidence. The QA person signs every release to the inspector — never the other way round.
The three iLEAN pieces applied to an always-ready FDA/EMA audit:
- iLEAN Tracer (Connect) — captures GMP evidence wherever it lives: the MES API, SCADA and LIMS files, signed training from the LMS, change control from SharePoint, calibrations from spreadsheets, the electronic audit trail of every read. Graduated capture adapted to each system: integrated where there is an API, intermediate where there is an old local PC, manual where there is only an analog panel — it does not force you to change anything.
- iLEAN Writer — maintains the live dossier by product, batch, process, SOP and deviation. Every new piece of data coming in from Tracer is added to the dossier it belongs to, with a Part 11 audit trail. On the day of the inspection, the dossier is assembled — it is not being built.
- iLEAN Agent — cross-references the dossier with the regulation in force (cGMP, EU GMP Annex 11, 21 CFR Part 11, ICH Q9/Q10), with the history of 483s and warning letters from your plant and from similar plants, and prepares the anticipated answers with their evidence. For a mock audit, it simulates the questions and flags where the dossier has a real gap. QA decides what is handed to the inspector and signs every release.
Pre-inspection sprint vs. live evidence with iLEAN
| Aspect | Classic pre-inspection sprint | With iLEAN Tracer + Writer + Agent |
|---|---|---|
| What triggers the work | The inspector's notice — 6-12 weeks of sprint | Continuous — the dossier lives between inspections |
| Where the evidence sits | Islands: MES, SCADA, LIMS, SharePoint, spreadsheets, LMS | Consolidated in a dossier by product/batch/process |
| An inspector's question | A treasure hunt + the QA director's memory | Consolidated dossier in seconds with a visible audit trail |
| Historical 483 | Prove by hand that it was closed | Closed CAPA mapped to the live status |
| Internal mock audit | An endurance test for QA | An actionable map of findings with real gaps |
| Getting back to normal pace | 3 months after the sprint | No sprint — nothing to get back from |
Impact estimate for your plant — to be validated with your numbers.
The block below is an estimate to be validated with the specific data of your plant. We put it forward so the committee has an order of magnitude; we refine it during the diagnostic.
- A GMP plant making oral solids, sterile products or ATMPs, one line or several, with an FDA and/or EMA inspection every 1-3 years and a typical pre-inspection sprint of 6-12 weeks.
- First value with iLEAN: a few weeks — usually with the live dossier of the first Pareto product and the historical 483s loaded and mapped.
- Expected reduction in pre-inspection sprint time: ≥30% on the very first inspection prepared with the system live. The curve keeps falling because the dossier keeps growing.
- Indicative payback between 4 and 9 months, driven by the cost of the QA team in sprint mode and by the cost of a 483 avoided or reclassified to a lower severity.
- Reference figure: in anchored tasks (summarizing, translating, recontextualizing a piece of data from one system into another — exactly what an inspection dossier does) the best models brought error below 1.5% [1]. The reliability of the dossier is not an act of faith.
And the quality manager's reasonable doubt
“What if the AI hands the inspector evidence we were not meant to show?” — the rule is strict: the agent prepares the response dossier with its evidence and audit trail; QA decides what is handed over and signs every release. The three rings exist for this: ring 1 (the OT network where the validated MES and SCADA live) never accepts inbound connections; the agent extracts the data outwards and leaves it signed in the dossier. The inspector sees what QA has signed, not what the AI thinks fits.
[1] OpenAI paper “Why Language Models Hallucinate”, 2025 — reliability of AI in anchored tasks.
What people ask about an always-ready FDA/EMA audit with AI
Which evidence is automated for an FDA/EMA inspection?
All the evidence that is anchored to process data: electronic batch records per batch, the Part 11 audit trail of every read and every signature, cleaning validation records with MACO and swab/rinse results, live calibration and preventive maintenance records, change control files with their evidence, signed personnel training linked to the SOP in force, deviations with root cause and closed CAPA, IQ/OQ/PQ validation with its revalidation delta if there were changes. The dossier for each product is maintained continuously — the inspection walks in and reads, it does not wait for anything to be rebuilt.
What about historical 483s and warning letters?
Historical Form 483s and warning letters are loaded into the system and cross-referenced with current processes. Every historical observation is mapped to the current evidence proving the CAPA was closed: if the FDA issued a 483 two years ago about cleaning multi-product equipment, the quality manager sees on one screen the live status of the cleaning validation, the deviations since then, the closed CAPA and the evidence chain. The inspector asks — the answer is assembled before they finish speaking.
How is the evidence accessed during the inspection?
Through a dedicated inspection room with read-only access for the inspector, traced and signed under Part 11. The inspector asks about a specific batch, a process, a deviation from 18 months ago — the system returns the consolidated dossier with a visible audit trail in seconds. The quality manager accompanies them, validates what is handed over and signs every release of information. The inspection stops being a treasure hunt in the archive and becomes a conversation with the data in front of you.
And for an internal mock audit?
A mock audit is exactly the same flow: the agent that prepares the dossier for FDA/EMA also prepares the dossier for an internal or customer audit (a pharma retailer's auditor, a sponsor in clinical trial manufacturing, a second party). The questions are simulated and the system flags the real gaps — places where the evidence is not complete or where the SOP in force does not match what is actually done. The mock audit goes from being an endurance test for QA to being an actionable map of findings.
How much does it cut inspection preparation time?
An estimate to be validated with your numbers: in a GMP plant with an FDA/EMA inspection every 1-3 years and a typical preparation sprint of 6-12 weeks, first value with iLEAN shows up within a few weeks — usually with the live dossier of the first Pareto product. Expected reduction in pre-inspection sprint time: ≥30% on the very first inspection prepared with the system live, and the curve keeps falling as the dossier grows. Indicative payback between 4 and 9 months, driven by the cost of the QA team in sprint mode and by the cost of a 483 avoided or reclassified.
Tell us your case and in 48h we'll send you the estimated ROI of an always-ready FDA/EMA inspection.
We work on your GMP plant's real data, not ours. Diagnostic with no commitment.
Request estimated ROI in 48h See pharma